Approval · Notice of Compliance 13037 · 2012
SUPRANE: Notice of Compliance 13037
Issued February 14, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13037
- Date
- February 14, 2012
- Company
- Baxter CorporationMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the Product Monograph
- Therapeutic class
- Inhalation Anaesthetic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUPRANE | Not yet assigned | — |
Medicinal ingredients
- DESFLURANE 1 ML per ML